Dual leucine zipper kinase (MAP3K12) modulators: a patent review (2010–2015)

References

• Holzman LB, Merritt SE, Fan G. Identification, molecular cloning, and characterization of dual leucine zipper bearing kinase. A novel serine/threonine protein kinase that defines a second subfamily of mixed lineage kinases. J Biol Chem. 1994;269(49):30808–30817.
   PubMed Web of Science ®Google Scholar
• Gallo KA, Johnson GL. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol. 2002;3(9):663–672.
   PubMed Web of Science ®Google Scholar
• Hirai S, Kawaguchi A, Suenaga J, et al. Expression of MUK/DLK/ZPK, an activator of the JNK pathway, in the nervous systems of the developing mouse embryo. Gene Expr Patterns. 2005;5(4):517–523.
   PubMed Web of Science ®Google Scholar
• Hirai S, Cui de F, Miyata T, et al., The c-Jun N-terminal kinase activator dual leucine zipper kinase regulates axon growth and neuronal migration in the developing cerebral cortex. J Neurosci. 2006;26(46):11992–12002.
   PubMed Web of Science ®Google Scholar
• Bloom AJ, Miller BR, Sanes JR, et al. The requirement for Phr1 in CNS axon tract formation reveals the corticostriatal boundary as a choice point for cortical axons. Genes Dev. 2007;21(20):2593–2606.
   PubMed Web of Science ®Google Scholar
• Sengupta Ghosh A, Wang B, Pozniak CD, et al. DLK induces developmental neuronal degeneration via selective regulation of proapoptotic JNK activity. J Cell Biol. 2011;194(5):751–764.
   PubMed Web of Science ®Google Scholar
• Pozniak CD, Sengupta Ghosh A, Gogineni A, et al., Dual leucine zipper kinase is required for excitotoxicity-induced neuronal degeneration. J Exp Med. 2013;210(12):2553–2567.
   PubMed Web of Science ®Google Scholar
• Oetjen E, Lechleiter A, Blume R, et al. Inhibition of membrane depolarisation-induced transcriptional activity of cyclic AMP response element binding protein (CREB) by the dual-leucine-zipper-bearing kinase in a pancreatic islet beta cell line. Diabetologia. 2006;49(2):332–342.
   PubMed Web of Science ®Google Scholar
• Robitaille H, Proulx R, Robitaille K, et al. The mitogen-activated protein kinase kinase kinase dual leucine zipper-bearing kinase (DLK) acts as a key regulator of keratinocyte terminal differentiation. J Biol Chem. 2005;280(13):12732–12741.
   PubMed Web of Science ®Google Scholar
• Germain L, Fradette J, Robitaille H, et al., The mixed lineage kinase leucine-zipper protein kinase exhibits a differentiation-associated localization in normal human skin and induces keratinocyte differentiation upon overexpression. J Investigative Dermatol. 2000;115(5):860–867.
   PubMed Web of Science ®Google Scholar
• Xu Z, Maroney AC, Dobrzanski P, et al. The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Mol Cell Biol. 2001;21(14):4713–4724.
   PubMed Web of Science ®Google Scholar
• Miller BR, Press C, Daniels RW, et al. A dual leucine kinase-dependent axon self-destruction program promotes Wallerian degeneration. Nat Neurosci. 2009;12(4):387–389.
   PubMed Web of Science ®Google Scholar
• Welsbie DS, Yang Z, Ge Y, et al., Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death. Proc Natl Acad Sci U S A. 2013;110(10):4045–4050.
   PubMed Web of Science ®Google Scholar
• Watkins TA, Wang B, Huntwork-Rodriguez S, et al., DLK initiates a transcriptional program that couples apoptotic and regenerative responses to axonal injury. Proc Natl Acad Sci U S A. 2013;110(10):4039–4044.
   PubMed Web of Science ®Google Scholar
• Chen X, Rzhetskaya M, Kareva T, et al., Antiapoptotic and trophic effects of dominant-negative forms of dual leucine zipper kinase in dopamine neurons of the substantia nigra in vivo. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience. 2008;28(3):672–680.
   PubMed Web of Science ®Google Scholar
• Shin Jung E, Cho Y, Beirowski B, et al. Dual leucine zipper kinase is required for retrograde injury signaling and axonal regeneration. Neuron. 2012;74(6):1015–1022.
   PubMed Web of Science ®Google Scholar
• Valakh V, Frey E, Babetto E, et al. Cytoskeletal disruption activates the DLK/JNK pathway, which promotes axonal regeneration and mimics a preconditioning injury. Neurobiol Dis. 2015;77:13–25.
   PubMed Web of Science ®Google Scholar
• Nix P, Bastiani M. DLK: The “Preconditioning” Signal for axon regeneration? Neuron. 2012;74(6):961–963.
   PubMed Web of Science ®Google Scholar
• Hammarlund M, Nix P, Hauth L, et al. Axon regeneration requires a conserved MAP kinase pathway. Science. 2009;323(5915):802–806.
   PubMed Web of Science ®Google Scholar
• Yan D, Wu Z, Chisholm AD, et al. The DLK-1 kinase promotes mRNA stability and local translation in C. elegans synapses and axon regeneration. Cell. 2009;138(5):1005–1018.
   PubMed Web of Science ®Google Scholar
• Xiong X, Collins CA. A conditioning lesion protects axons from degeneration via the Wallenda/DLK MAP kinase signaling cascade. J Neurosci. 2012;32(2):610–615.
   PubMed Web of Science ®Google Scholar
• Xiong X, Wang X, Ewanek R, et al. Protein turnover of the Wallenda/DLK kinase regulates a retrograde response to axonal injury. J Cell Biol. 2010;191(1):211–223.
   PubMed Web of Science ®Google Scholar
• Ferraris D, Yang Z, Welsbie D. Dual leucine zipper kinase as a therapeutic target for neurodegenerative conditions. Future Med Chem. 2013;5(16):1923–1934.
   PubMed Web of Science ®Google Scholar
• Phu DT, Wallbach M, Depatie C, et al. Regulation of the CREB coactivator TORC by the dual leucine zipper kinase at different levels. Cell Signal. 2011;23(2):344–353.
   PubMed Web of Science ®Google Scholar
• Plaumann S, Blume R, Börchers S, et al. Activation of the dual-leucine-zipper-bearing kinase and induction of beta-cell apoptosis by the immunosuppressive drug cyclosporin A. Mol Pharmacol. 2008;73(3):652–659.
   PubMed Web of Science ®Google Scholar
• Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98–107.
   PubMed Web of Science ®Google Scholar
• Wallbach M, Escobar JD, Babaeikelishomi R, et al., Distinct functions of the dual leucine zipper kinase depending on its subcellular localization. Cell Signal. 2016;28:272–283.
   PubMed Web of Science ®Google Scholar
• Stahnke MJ, Dickel C, Schroder S, et al., Inhibition of human insulin gene transcription and MafA transcriptional activity by the dual leucine zipper kinase. Cell Signal. 2014;26(9):1792–1799.
   PubMed Web of Science ®Google Scholar
• Fan G, Merritt SE, Kortenjann M, et al. Dual Leucine Zipper-bearing Kinase (DLK) Activates p46SAPK and p38mapk but Not ERK2. J Biol Chem. 1996;271(40):24788–24793.
   PubMed Web of Science ®Google Scholar
• Nakata K, Abrams B, Grill B, et al., Regulation of a DLK-1 and p38 MAP Kinase Pathway by the Ubiquitin Ligase RPM-1 Is Required for Presynaptic Development. Cell. 2005;120(3):407–420.
   PubMed Web of Science ®Google Scholar
• Mata M, Merritt SE, Fan G, et al. Characterization of dual leucine zipper-bearing kinase, a mixed lineage kinase present in synaptic terminals whose phosphorylation state is regulated by membrane depolarization via calcineurin. J Biol Chem. 1996;271(28):16888–16896.
   PubMed Web of Science ®Google Scholar
• Collins CA, Wairkar YP, Johnson SL, et al. Highwire restrains synaptic growth by attenuating a MAP kinase signal. Neuron. 2006;51(1):57–69.
   PubMed Web of Science ®Google Scholar
• Daviau A, Proulx R, Robitaille K, et al., Down-regulation of the mixed-lineage dual leucine zipper-bearing kinase by heat shock protein 70 and its co-chaperone CHIP. J Biol Chem. 2006;281(42):31467–31477.
   PubMed Web of Science ®Google Scholar
• Huntwork-Rodriguez S, Wang B, Watkins T, et al., JNK-mediated phosphorylation of DLK suppresses its ubiquitination to promote neuronal apoptosis. J Cell Biol. 2013;202(5):747–763.
   PubMed Web of Science ®Google Scholar
• Xu Z, Kukekov NV, Greene LA. Regulation of apoptotic c-Jun N-terminal kinase signaling by a stabilization-based feed-forward loop. Mol Cell Biol. 2005;25(22):9949–9959.
   PubMed Web of Science ®Google Scholar
• Robitaille K, Daviau A, Lachance G, et al. Calphostin C-induced apoptosis is mediated by a tissue transglutaminase-dependent mechanism involving the DLK/JNK signaling pathway. Cell Death Differ. 2008;15(9):1522–1531.
   PubMed Web of Science ®Google Scholar
• Nihalani D, Wong H, Verma R, et al. Src family kinases directly regulate jip1 module dynamics and activation. Mol Cell Biol. 2007;27(7):2431–2441.
   PubMed Web of Science ®Google Scholar
• Nihalani D, Meyer D, Pajni S, et al. Mixed lineage kinase-dependent JNK activation is governed by interactions of scaffold protein JIP with MAPK module components. Embo J. 2001;20(13):3447–3458.
   PubMed Web of Science ®Google Scholar
• Nihalani D, Wong HN, Holzman LB. Recruitment of JNK to JIP1 and JNK-dependent JIP1 phosphorylation regulates jnk module dynamics and activation. J Biol Chem. 2003;278(31):28694–28702.
   PubMed Web of Science ®Google Scholar
• Leung IW-L, Lassam N. The kinase activation loop is the key to mixed lineage kinase-3 activation via both autophosphorylation and hematopoietic progenitor kinase 1 phosphorylation. J Biol Chem. 2001;276(3):1961–1967.
   PubMed Web of Science ®Google Scholar
• Zack DJ, Welsbie DS, inventors; Johns Hopkins University [US], assignee. Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders. WO2013134766 (A2). 2013. in application
   Google Scholar
• Watts R, Chen M, Lewcock JW, et al., inventors; Genentech Inc [US], assignee. Modulation of axon degeneration. WO2010048446 (A3). 2010. in application.
   Google Scholar
• Lewcock JW, Pozniak C, Sengupta-Ghosh A, inventors; Genentech Inc [US]; Hoffmann La Roche [CH], assignee. Modulation of axon degeneration. WO2011050192 (A1). 2011. in application.
   Google Scholar
• DiAntonio A, Miller BR, Milbrandt JD, et al., inventors; University of Washington [US], assignee. Methods and compositions for inhibition of axonal degeneration by modulation of the DLK/JNK pathway. US8754060 (B2). 2014.
   Google Scholar
• Bustos D, Huntwork-Rodriguez S, Kirkpatrick D, et al., inventors; Genentech Inc (US), Hoffmann-La Roche (CH), assignee. Methods of modulating DLK stability. WO2014134349 (A1). 2014. in application.
   Google Scholar
• Nihalani D, Merritt S, Holzman LB. identification of structural and functional domains in mixed lineage kinase dual leucine zipper-bearing kinase required for complex formation and stress-activated protein kinase activation. J Biol Chem. 2000;275(10):7273–7279.
   PubMed Web of Science ®Google Scholar
• Cohen P. Protein kinases–the major drug targets of the twenty-first century? Nat Rev Drug Discov. 2002;1(4):309–315.
   PubMed Web of Science ®Google Scholar
• Capdeville R, Buchdunger E, Zimmermann J, et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1(7):493–502.
   PubMed Web of Science ®Google Scholar
• Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science. 2002;298(5600):1912–1934.
   PubMed Web of Science ®Google Scholar
• Bain J, Plater L, Elliott M, et al., The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408(3):297–315.
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK, et al., A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127–132.
   PubMed Web of Science ®Google Scholar
• Davis MI, Hunt JP, Herrgard S, et al., Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29(11):1046–1051.
   PubMed Web of Science ®Google Scholar
• Maroney AC, Finn JP, Connors TJ, et al., Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem. 2001;276(27):25302–25308.
   PubMed Web of Science ®Google Scholar
• Becknell NC, Brown PD, Dandu R, et al., inventors; Cephalon Inc, Frazer, PA (US), assignee. Novel fused pyrrolocarbazoles. US8383813 (B2). 2013. Patent issued.
   Google Scholar
• Hudkins RL, Dandu R, Tao M, et al., inventors; Cephalon Inc [US], assignee. Novel fused pyrrolocarbazoles. US8084472 (B2). 2011. Patent issued.
   Google Scholar
• Patel S, Cohen F, Dean BJ, et al., Discovery of dual leucine zipper kinase (DLK, MAP3K12) Inhibitors with activity in neurodegeneration models. J Med Chem. 2015;58(1):401–418.
   PubMed Web of Science ®Google Scholar
• Patel S, Harris SF, Gibbons P, et al., Scaffold-hopping and structure-based discovery of potent, selective, and brain penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine inhibitors of dual leucine zipper kinase (DLK, MAP3K12). J Med Chem. 2015;58(20):8182–8199.
   PubMed Web of Science ®Google Scholar
• Cohen F, Huestis M, Ly C, et al., inventors; Hoffmann La Roche [CH]; Genentech Inc [US], assignee. Substituted dipyridylamines and uses thereof. WO2013174780 (A1). 2013. in application.
   Google Scholar
• Estrada A, Liu W, Patel S, et al., inventors; Hoffmann La Roche [CH]; Genentech Inc[US], assignee. 3-substituted pyrazoles and use as DLK inhibitors. WO2014111496 (A1). 2014. in application.
   Google Scholar
• Chen KX, Dong L, Estrada A, et al., inventors; Hoffmann La Roche [CH]; Genentech Inc [US], assignee. Biheteroaryl compounds and uses thereof. WO2014177060 (A1). 2014. in application.
   Google Scholar
• Lyssikatos JP, Liu W, Siu M, et al., inventors; Hoffmann La Roche [CH]; Genentech Inc [US], assignee. Pyrazole derivatives and uses thereof as inhibitors of DLK. WO2015091889 (A1). 2015. in application.
   Google Scholar
• Abdel-Magid AF. Dual leucine zipper kinase inhibitors: potential treatments for neurodegenerative diseases. ACS Med Chem Lett. 2015;6(1):11–12.
   PubMed Web of Science ®Google Scholar
• Qian F, Engst S, Yamaguchi K, et al., Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 2009;69(20):8009–8016.
   PubMed Web of Science ®Google Scholar
• Han B, Yang F, Wang L, inventors; Faming Zhuanlin Shenqing, assignee. 2-(Acylamino)benzimidazole derivatives as protease inhibitors and their preparation, pharmaceutical compositions and use in the treatment of DLK related diseases. CN104370897 (A). 2015. in application.
   Google Scholar
• Han B, Wang L, Wang S, inventors; Faming Zhuanli Shenquing, assignee. Protease inhibitor and preparing method and use thereof. CN104151302 (A). 2014. in application.
   Google Scholar
• Han B, Yang F, Wang L, inventors; Faming Zhuanli Shenqing, assignee. Preparation of dual-leucine zipper kinase inhibitors. CN104370925 (A). 2015. in application.
   Google Scholar
• Han B, Gao Y, Wang L, inventors; Faming Zhuanli Shenqing, assignee. Preparation of tetrazolo[1,5-a]pyrimidine-6-carboxamides as protease inhibitors. CN104387391 (A). 2015. in application.
   Google Scholar
• Han B, Xing R, inventors; Faming Zhuanli Shenqing, assignee. 4-Cyanoimidazole-2-carboxamide derivatives as protease inhibitors and their preparation, pharmaceutical compositions and use in the treatment of DLK related diseases. CN104370880 (A). 2015. in application.
   Google Scholar
• Han B, Yang F, Wang L, inventors; Faming Zhuanli Shenqing, assignee. Preparation of 7-phenyl-5-methyl-N-(pyridin-3-yl)-4,5,6,7-tetrahydrotetrazolo[1,5-a]pyrimidine-6-carboxamides as DLK inhibitors. CN104119340 (A). 2014. in application.
   Google Scholar
• Han B, Yang F, Wang L, inventors; Faming Zhuanli Shenqing, assignee. Protease inhibitors, preparation method and application thereof. CN104119341 (A). 2014. in application.
   Google Scholar
• Bastiani MJ, Jorgensen E, Nix P, et al., inventors; University of Utah Research Foundation, Salt Lake City, UT (US), assignee. Methods and Compositions Related to DLK-1 and the P38 MAPK Pathway in Nerve Regeneration. US2013190388 (A1). 2013. in application.
   Google Scholar
• Holland SM, Collura KM, Ketschek A, et al., Palmitoylation controls DLK localization, interactions and activity to ensure effective axonal injury signaling. Proc Natl Acad Sci U S A. 2016;113(3):763–768.
   PubMed Web of Science ®Google Scholar
• Lorenz K, Stathopoulou K, Schmid E, et al. Heart failure-specific changes in protein kinase signalling. Pflugers Arch. 2014;466(6):1151–1162.
   PubMed Web of Science ®Google Scholar